$IBRX
ImmunityBio, Inc. Stock $ibrx

$ibrx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000132611023000098 Filed on August 08, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$82.00K	$41.00K	$73.00K
YoY Change	-30.51%	17.14%	-81.28%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$82.00K	$41.00K
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$31.82M	$32.02M	$26.22M
YoY Change	64.76%	93.17%	-6.08%
% of Gross Profit	38800.0%	78092.68%
Research & Development	$48.40M	$53.17M	$57.58M
YoY Change	-32.41%	-15.72%	11.25%
% of Gross Profit	59026.83%	129678.05%
Depreciation & Amortization	$4.100M	$4.200M	$5.226M
YoY Change	0.0%	7.69%	45.37%
% of Gross Profit	5000.0%	10243.9%
Operating Expenses	$80.22M	$85.19M	$84.29M
YoY Change	-11.77%	6.94%	5.81%
Operating Profit	-$80.14M	-$85.15M
YoY Change	-11.75%	6.94%
Interest Expense	$35.02M	$32.24M	-$22.50M
YoY Change	108.91%	232.39%	100.68%
% of Operating Profit
Other Income/Expense, Net	-$15.51M	-$53.07M	-$896.0K
YoY Change	-23.83%	248.83%	238.11%
Pretax Income	-$95.64M	-$138.2M	-$108.3M
YoY Change	-13.96%	45.74%	18.28%
Income Tax	$0.00	$0.00	$34.00K
% Of Pretax Income
Net Earnings	-$95.58M	-$137.9M	-$108.2M
YoY Change	-13.84%	45.77%	18.58%
Net Earnings / Revenue	-116563.41%	-336290.24%	-148239.73%
Basic Earnings Per Share	-$0.19	-$0.32
Diluted Earnings Per Share	-$0.19	-$0.32	-$0.27
COMMON SHARES
Basic Shares Outstanding	456.2M shares	436.0M shares	400.3M shares
Diluted Shares Outstanding	498.4M shares	437.5M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$179.7M	$45.95M	$107.2M
YoY Change	61.78%	-44.59%	-66.2%
Cash & Equivalents	$178.0M	$43.51M	$104.6M
Short-Term Investments	$1.700M	$2.448M	$2.543M
Other Short-Term Assets	$4.384M	$4.554M	$3.732M
YoY Change	35.48%	51.85%	-32.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$2.325M	$2.025M	$1.890M
Total Short-Term Assets	$215.1M	$66.83M	$140.6M
YoY Change	50.31%	-41.89%	-57.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$152.0M	$151.5M	$143.7M
YoY Change	16.53%	26.83%	73.37%
Goodwill
YoY Change
Intangibles	$18.47M	$18.99M	$20.00M
YoY Change	-9.79%	-12.63%	1308.66%
Long-Term Investments	$817.0K	$841.0K	$840.0K
YoY Change	0.74%	-7.99%	2.19%
Other Assets	$3.427M	$3.774M	$4.860M
YoY Change	-33.24%	-37.35%	-28.27%
Total Long-Term Assets	$217.3M	$224.4M	$221.8M
YoY Change	3.57%	10.69%	64.81%
TOTAL ASSETS
Total Short-Term Assets	$215.1M	$66.83M	$140.6M
Total Long-Term Assets	$217.3M	$224.4M	$221.8M
Total Assets	$432.4M	$291.2M	$362.4M
YoY Change	22.52%	-8.34%	-22.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.82M	$25.49M	$21.02M
YoY Change	-2.07%	41.18%	84.06%
Accrued Expenses	$64.87M	$62.34M	$41.83M
YoY Change	40.35%	19.07%	-18.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$481.9M	$431.9M
YoY Change		60.59%	44.33%
Long-Term Debt Due	$2.338M	$36.62M	$4.886M
YoY Change	-57.33%	780.66%	23.92%
Total Short-Term Liabilities	$90.32M	$613.5M	$500.9M
YoY Change	27.5%	63.14%	35.74%
LONG-TERM LIABILITIES
Long-Term Debt	$673.6M	$250.1M	$241.3M
YoY Change	1.88%	-19.97%	-21.22%
Other Long-Term Liabilities	$467.0K	$473.0K	$457.0K
YoY Change	-17.93%	63.1%	83.53%
Total Long-Term Liabilities	$467.0K	$473.0K	$457.0K
YoY Change	-17.93%	63.1%	83.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$90.32M	$613.5M	$500.9M
Total Long-Term Liabilities	$467.0K	$473.0K	$457.0K
Total Liabilities	$843.1M	$936.4M	$812.2M
YoY Change	7.81%	26.59%	13.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.700B	-$2.600B	-$2.400B
YoY Change	17.39%	18.18%	22.33%
Common Stock	$2.316B	$1.991B	$1.931B
YoY Change	25.6%	14.43%	12.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$411.7M	-$642.1M	-$447.3M
YoY Change
Total Liabilities & Shareholders Equity	$432.4M	$291.2M	$362.4M
YoY Change	22.52%	-8.34%	-22.72%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$95.58M	-$137.9M	-$108.2M
YoY Change	-13.84%	45.77%	18.58%
Depreciation, Depletion And Amortization	$4.100M	$4.200M	$5.226M
YoY Change	0.0%	7.69%	45.37%
Cash From Operating Activities	-$87.41M	-$79.77M	-$90.73M
YoY Change	8.44%	-12.58%	26.64%
INVESTING ACTIVITIES
Capital Expenditures	$5.679M	$8.526M	$18.93M
YoY Change	-135.64%	-153.46%	-281.98%
Acquisitions
YoY Change
Other Investing Activities	-$9.960M	-$78.00K	$37.00K
YoY Change	-167.45%	-100.06%	-100.03%
Cash From Investing Activities	-$15.63M	-$8.604M	-$18.89M
YoY Change	1238.1%	-107.37%	-86.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	237.5M	43.41M	109.9M
YoY Change	91.56%	-289513.33%	-66.27%
NET CHANGE
Cash From Operating Activities	-87.41M	-79.77M	-90.73M
Cash From Investing Activities	-15.63M	-8.604M	-18.89M
Cash From Financing Activities	237.5M	43.41M	109.9M
Net Change In Cash	134.5M	-44.97M	319.0K
YoY Change	218.51%	-276.99%	-99.73%
FREE CASH FLOW
Cash From Operating Activities	-$87.41M	-$79.77M	-$90.73M
Capital Expenditures	$5.679M	$8.526M	$18.93M
Free Cash Flow	-$93.08M	-$88.30M	-$109.7M
YoY Change	43.95%	17.26%	79.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2	ibrx	Convertible Notes Payable Current Fair Value ConvertibleNotesPayableCurrentFairValue	36618000	usd
CY2022Q4	ibrx	Convertible Notes Payable Current Fair Value ConvertibleNotesPayableCurrentFairValue	0	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	27799000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	21636000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	473000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	457000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	936410000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	812176000	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	440673897	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	440673897	shares
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	163800	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	163800	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	44000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1990590000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1930936000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2632710000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2378488000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	183000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-642116000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-447327000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-3067000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-2493000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-645183000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-449820000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	291227000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	362356000	usd
CY2023Q2	us-gaap	Revenues Revenues	41000	usd
CY2022Q2	us-gaap	Revenues Revenues	35000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32018000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16575000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	85186000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	79657000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-85145000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-79622000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-61000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1800000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	32235000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	9698000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3957000	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3900000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10019000	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-6768000	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	185000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53068000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15213000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-138213000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94835000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-138213000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-94835000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-334000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	437456657	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	437456657	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	397937333	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	397937333	shares
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-6000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	149000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-119000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	257000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-223000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-114000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-138220000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-94578000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-255019000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-197947000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-334000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-247000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-574000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-419000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-137886000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94331000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-254445000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-197528000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-449820000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10878000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	126000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	357000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-216000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-116583000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-531716000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-138213000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-645183000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-243913000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10024000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	372000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-371000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-102998000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-337556000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	15000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	257000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-94835000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-421974000	usd
	us-gaap	Profit Loss ProfitLoss	-254796000	usd
	us-gaap	Profit Loss ProfitLoss	-197833000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	23824000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	744000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	21940000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20199000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-17535000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9363000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8534000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-6768000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	5026000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	6178000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3233000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2805000	usd
	ibrx	Transaction Costs Warrant Liability TransactionCostsWarrantLiability	984000	usd
	ibrx	Transaction Costs Warrant Liability TransactionCostsWarrantLiability	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-258000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-452000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1308000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	123000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	222000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11240000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14474000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1047000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-699000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-869000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	6535000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	27864000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	602000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	-1232000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	41000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1321000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2194000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-164083000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-166182000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16954000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43296000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	236000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	34207000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	102000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33657000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	113434000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21229000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17088000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47359000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	59700000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	417000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	387000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	261000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	38000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-313000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-264000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61135000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-119056000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104965000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181280000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	43830000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62224000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43506000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61900000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	324000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	324000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	43830000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62224000	usd
	us-gaap	Interest Paid Net InterestPaidNet	25520000	usd
	us-gaap	Interest Paid Net InterestPaidNet	11149000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	ibrx	Issuance Of Warrants IssuanceOfWarrants	23698000	usd
	ibrx	Issuance Of Warrants IssuanceOfWarrants	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11992000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13454000	usd
	ibrx	Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	208000	usd
	ibrx	Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-42000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13986000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to unaudited condensed consolidated financial statements, the terms “ImmunityBio,” “the company,” “we,” “us,” and “our” refer to ImmunityBio, Inc. and its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system—natural killer (NK) cells, dendritic cells, and macrophages—and the adaptive immune system—B cells and T cells—in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an “immunological memory” that confers long-term benefit for the patient. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (N-803), our novel antibody cytokine fusion protein, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations in combination with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Guérin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG) from the U.S. Food and Drug Administration (FDA) for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022, we announced the submission of a Biologics License Application (BLA) to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease. On May 9, 2023, the FDA delivered a complete response letter (CRL) to us regarding the BLA, indicating that the FDA had determined that it cannot approve the BLA in its present form, and the FDA made recommendations to address the issues raised. The deficiencies relate to the FDA’s pre-license inspection of the company’s third-party contract manufacturing organizations (CMOs), among other items. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. The FDA further provided recommendations specific to additional Chemistry, Manufacturing and Controls (CMC) issues and assays to be resolved. The CRL does not request new preclinical studies or Phase 3 clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company’s resubmission, as well as a safety update. The company has submitted a formal meeting request and the associated briefing book to the FDA and plans to diligently address and resolve the issues identified in the CRL and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all.</span></div>Our platforms include 13 novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in multiple active clinical trials involving our agents, some of which are being sponsored by ImmunityBio and others are investigator-led studies. Many of these trials are in Phase 2 or 3 development across several indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV).
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2600000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-164100000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	101174764	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17952702	shares
CY2023Q2	ibrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	5986000	usd
CY2022Q4	ibrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11704000	usd
CY2023Q2	ibrx	Prepaid Services PrepaidServices	3344000	usd
CY2022Q4	ibrx	Prepaid Services PrepaidServices	8013000	usd
CY2023Q2	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	2309000	usd
CY2022Q4	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	2195000	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1399000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2282000	usd
CY2023Q2	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	1254000	usd
CY2022Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	usd
CY2023Q2	us-gaap	Supplies Supplies	0	usd
CY2022Q4	us-gaap	Supplies Supplies	2160000	usd
CY2023Q2	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	0	usd
CY2022Q4	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	1417000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4554000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3732000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18846000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31503000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	229066000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	212911000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	77579000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69252000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	151487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143659000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	4200000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	3900000	usd
	us-gaap	Depreciation Depreciation	8300000	usd
	us-gaap	Depreciation Depreciation	7700000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1399000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1399000	usd
CY2023Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	21797000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2805000	usd
CY2023Q2	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	0	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18992000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21229000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1935000	usd
CY2022Q4	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	681000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18613000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1390000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1390000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	22619000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1935000	usd
CY2022Q4	ibrx	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	681000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20003000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1020000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2040000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2040000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2040000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2040000	usd
CY2023Q2	ibrx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	8413000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17593000	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	17486000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12068000	usd
CY2023Q2	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	15035000	usd
CY2022Q4	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1930000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7920000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6685000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6791000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6040000	usd
CY2023Q2	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	5495000	usd
CY2022Q4	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	4985000	usd
CY2023Q2	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	1428000	usd
CY2022Q4	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	7072000	usd
CY2023Q2	ibrx	Financing Obligation Current FinancingObligationCurrent	0	usd
CY2022Q4	ibrx	Financing Obligation Current FinancingObligationCurrent	1417000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	818000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1628000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	62335000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41825000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	592000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	94000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	644000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	876000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1940000	usd
CY2023Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-393000	usd
CY2022Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-1871000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-258000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-452000	usd
CY2023Q2	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-260000	usd
CY2022Q2	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-454000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1503000	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-119000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-6000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-119000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-61000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1800000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	612000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-134000	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	5000	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	5000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	25000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	25000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	32235000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	9698000	usd
	us-gaap	Interest Expense InterestExpense	62051000	usd
	us-gaap	Interest Expense InterestExpense	18189000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1126000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	87000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1040000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	970000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	94000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	876000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12	security
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	496000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	60000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	382000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	27000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	876000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42555000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45788000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	96000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	135000	usd
CY2023Q2	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	42651000	usd
CY2022Q4	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	45923000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5984000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2650000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	81000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	77000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44558000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47951000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	64000	usd
CY2023Q2	ibrx	Lease Liability LeaseLiability	50645000	usd
CY2022Q4	ibrx	Lease Liability LeaseLiability	50742000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.106
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.117
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.117
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	2922000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	2942000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5843000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5250000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	979000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2029000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q2	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	22000	usd
CY2022Q2	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	0	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	45000	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	0	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	975000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	934000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1945000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2116000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	4898000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	3876000	usd
	us-gaap	Lease Cost LeaseCost	9862000	usd
	us-gaap	Lease Cost LeaseCost	7366000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5842000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5091000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	38000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
	ibrx	Operating Lease Payments Related To Options To Extend Lease Terms OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms	11500000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3930000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	44000	usd
CY2023Q2	ibrx	Lease Liability To Be Paid Remainder Of Fiscal Year LeaseLiabilityToBePaidRemainderOfFiscalYear	3974000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12119000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2023Q2	ibrx	Lease Liability To Be Paid Year One LeaseLiabilityToBePaidYearOne	12185000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12145000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q2	ibrx	Lease Liability To Be Paid Year Two LeaseLiabilityToBePaidYearTwo	12145000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10290000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q2	ibrx	Lease Liability To Be Paid Year Three LeaseLiabilityToBePaidYearThree	10290000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8209000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q2	ibrx	Lease Liability To Be Paid Year Four LeaseLiabilityToBePaidYearFour	8209000	usd
CY2023Q2	ibrx	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	23248000	usd
CY2023Q2	ibrx	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2023Q2	ibrx	Lease Liability To Be Paid After Year Four LeaseLiabilityToBePaidAfterYearFour	23248000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	69941000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	110000	usd
CY2023Q2	ibrx	Lease Liability To Be Paid LeaseLiabilityToBePaid	70051000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19399000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2023Q2	ibrx	Lease Liability Undiscounted Excess Interest LeaseLiabilityUndiscountedExcessInterest	19406000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	50542000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	103000	usd
CY2023Q2	ibrx	Lease Liability LeaseLiability	50645000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-6800000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11062000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10175000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21940000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20199000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11062000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10175000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21940000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20199000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9262926	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.87
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4848000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	949578	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.99
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	107620	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	102162	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.30
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10002722	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.35
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	640000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	5963111	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.38
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	640000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3445499	shares

Files In Submission

Name	View Source	Status
0001326110-23-000098-index-headers.html	Edgar Link	pending
0001326110-23-000098-index.html	Edgar Link	pending
0001326110-23-000098.txt	Edgar Link	pending
0001326110-23-000098-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibrx-20230630.htm	Edgar Link	pending
ibrx-20230630.xsd	Edgar Link	pending
ibrx-20230630x10qexhibit102.htm	Edgar Link	pending
ibrx-20230630x10qexhibit311.htm	Edgar Link	pending
ibrx-20230630x10qexhibit312.htm	Edgar Link	pending
ibrx-20230630x10qexhibit321.htm	Edgar Link	pending
ibrx-20230630x10qexhibit322.htm	Edgar Link	pending
ibrx-20230630_g1.jpg	Edgar Link	pending
ib_logoxfinalxcolorx02x2021a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
ibrx-20230630_cal.xml	Edgar Link	unprocessable
ibrx-20230630_def.xml	Edgar Link	unprocessable
ibrx-20230630_lab.xml	Edgar Link	unprocessable
ibrx-20230630_pre.xml	Edgar Link	unprocessable
ibrx-20230630_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBRX
ImmunityBio, Inc. Stock $ibrx

2023 Q3 Form 10-Q Financial Statement

#000132611023000098 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX ImmunityBio, Inc. Stock $ibrx

2023 Q3 Form 10-Q Financial Statement

#000132611023000098 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX
ImmunityBio, Inc. Stock $ibrx